Brought to you by 
Juventas brings in $11.6mm through its Series B round; financing now at $22.2mm
13 May 2015
Executive Summary
Cardiovascular drug developer Juventas Therapeutics Inc. (formerly AcelleRX Therapeutics) has raised $11.6mm through its Series B venture round. New Science Ventures led the financing and was joined by Takeda Ventures and undisclosed investors. The money will be used for two Phase II studies of JVS100--one to test for safety and effectiveness in heart failure patients, the other for critical limb ischemia.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Juventas brings in $11.6mm through its Series B round; financing now at $22.2mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice